The ability to create health information technology tools is happening much faster than the ability to figure out what to do with them, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
The ability to create health information technology tools is happening much faster than the ability to figure out what to do with them, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.
Transcript
How have health technologies helped enhance high-quality cancer care and improve outcomes for patients?
So, the great challenge we’ve always faced is how do we keep pace with the new technologies that are coming down the pipe? Because we’re getting so good at developing new technologies, whether it’s informatics or it’s precision medicine or new drug therapies or diagnostics. Our ability to create these new tools is much faster than our ability to figure out what to do with it, because when you want to measure outcomes improvement, it requires acquisition of the technology, which has certain expense to it. It requires learning how to use it properly, adapting it to its use, and then measuring the outcomes.
There may be many intermediary steps between the technology and actually the outcomes measures, so it’s a real difficult question to answer: how have these improved our outcomes? It’s really that lack of ability to measure adequately that’s slowing us down more than anything else at this time.
Having said that, I think we are seeing real progress with the use of information technology. I think, without a question, if you ask most physicians, I think, would they rather go back to paper charts? The answer would probably be "no." If you asked patients, would you like to go back to the age where you could not get a patient portal? Find out your lab tests? I mean you always want more, but would you want to go back to the point where you had nothing? People would say "no, that’s not a good idea either."
So, I think that we are frustrated with how slow it goes, but that tends to make us not realize how far we’ve gone and where we used to be just a short while ago.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
February 18th 2025Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).
Read More